Literature DB >> 31302243

The endocannabinoid system is affected by cholesterol dyshomeostasis: Insights from a murine model of Niemann Pick type C disease.

Sergio Oddi1, Paola Caporali2, Jessica Dragotto2, Antonio Totaro3, Marzia Maiolati2, Lucia Scipioni3, Clotilde Beatrice Angelucci4, Cristina Orsini5, Sonia Canterini2, Cinzia Rapino4, Mauro Maccarrone6, Maria Teresa Fiorenza7.   

Abstract

The dyshomeostasis of intracellular cholesterol trafficking is typical of the Niemann-Pick type C (NPC) disease, a fatal inherited lysosomal storage disorder presenting with progressive neurodegeneration and visceral organ involvement. In light of the well-established relevance of cholesterol in regulating the endocannabinoid (eCB) system expression and activity, this study was aimed at elucidating whether NPC disease-related cholesterol dyshomeostasis affects the functional status of the brain eCB system. To this end, we exploited a murine model of NPC deficiency for determining changes in the expression and activity of the major molecular components of the eCB signaling, including cannabinoid type-1 and type-2 (CB1 and CB2) receptors, their ligands, N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), along with their main synthesizing/inactivating enzymes. We found a robust alteration of distinct components of the eCB system in various brain regions, including the cortex, hippocampus, striatum and cerebellum, of Npc1-deficient compared to wild-type pre-symptomatic mice. Changes of the eCB component expression and activity differ from one brain structure to another, although 2-AG and AEA are consistently found to decrease and increase in each structure, respectively. The thorough biochemical characterization of the eCB system was accompanied by a behavioral characterization of Npc1-deficient mice using a number of paradigms evaluating anxiety, locomotor activity, spatial learning/memory abilities, and coping response to stressful experience. Our findings provide the first description of an early and region-specific alteration of the brain eCB system in NPC and suggest that defective eCB signaling could contribute at producing and/or worsening the neurological symptoms of this disorder.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavioral phenotyping; Endocannabinoid system biochemistry; Genetic mouse models; Lysosomal storage disorders

Mesh:

Substances:

Year:  2019        PMID: 31302243     DOI: 10.1016/j.nbd.2019.104531

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  4 in total

1.  Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes.

Authors:  Valéria de Almeida; Gabriela Seabra; Guilherme Reis-de-Oliveira; Giuliana S Zuccoli; Priscila Rumin; Mariana Fioramonte; Bradley J Smith; Antonio W Zuardi; Jaime E C Hallak; Alline C Campos; José A Crippa; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-27       Impact factor: 5.760

2.  Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.

Authors:  Camilla Di Meo; Daniel Tortolani; Sara Standoli; Clotilde Beatrice Angelucci; Federico Fanti; Alessandro Leuti; Manuel Sergi; Salam Kadhim; Eric Hsu; Cinzia Rapino; Mauro Maccarrone
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

Review 3.  New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy.

Authors:  Edward H Schuchman; Maria D Ledesma; Calogera M Simonaro
Journal:  Orphanet J Rare Dis       Date:  2021-03-25       Impact factor: 4.123

4.  Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling.

Authors:  Adrián Bartoll; Ana Toledano-Zaragoza; Josefina Casas; Manuel Guzmán; Edward H Schuchman; María Dolores Ledesma
Journal:  EMBO Mol Med       Date:  2020-10-05       Impact factor: 12.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.